Skip to main content

THE PRODUCTION OF A 3D HUMAN TISSUE DISEASE PLATFORM TO ENABLE REGENERATIVE MEDICINE THERAPY DEVELOPMENT

Obiettivo

This project will focus on the production of an in vitro human disease tissue platform technology to enable and accelerate the development of regenerative medicine therapies for a diverse range of diseases. The concept will be realised by the in vitro generation of 3D human tissues cultured from human induced Pluripotent Stem (iPS) cells. Initially a library of adult cells will be generated from patients with a range of genetic diseases. These cells will subsequently be used to generate iPS cell cultures in optimised conditions, with the resultant cells being differentiated into key cell types. These differentiated cells will then be integrated onto 3D tissue bioreactors operating in an optimised variable perfusion environment producing the 3D human tissue disease cultures. The bioreactors will be constructed using a range of innovative microfluidic techniques to produce systems compatible with analysis systems commonly used in laboratories worldwide. The development of a platform technology producing 3D human tissue disease cultures will enable the generation of fully differentiated cell types and thus allow diseases to be effectively modelled at a population relevant scale in 3D human tissues in vitro. The resultant major benefit of the system is that it will allow regenerative therapies to be developed and tested on batteries of human tissues in the laboratory in a rapid, cost effective manner relevant to the in vivo state. To develop and validate the platform technology within the lifetime of the project liver hepatocyte cells and tissues will be generated due to their scientific and commercial significance from a population relevant range of patients with inherited metabolic disorders (IMDs). Therefore this project will significantly advance the state of the art and constitute a significant step forward for the regenerative medicine industry producing a key platform resource.

Campo scientifico

  • /ingegneria e tecnologia/biotecnologia ambientale/biorisanamento/bioreattore

Invito a presentare proposte

FP7-HEALTH-2011-two-stage
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP-FP - Small or medium-scale focused research project

Coordinatore

Cn Bio Innovations Limited
Indirizzo
30 Upper High Street
OX9 3EZ Thame
United Kingdom
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contributo UE
€ 451 500
Contatto amministrativo
David Hughes (Dr.)

Partecipanti (4)

Takara Bio Europe AB
Svezia
Contributo UE
€ 1 216 325
Indirizzo
Arvid Wallgrens Backe
413 46 Göteborg
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Jenny Goodwin (Ms.)
TRANSTISSUE TECHNOLOGIES GMBH
Germania
Contributo UE
€ 304 350
Indirizzo
Chariteplatz 1 / Virchowweg 11
10117 Berlin
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Christian Kaps (Dr.)
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
Contributo UE
€ 630 280
Indirizzo
Trinity Lane The Old Schools
CB2 1TN Cambridge
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Renata Schaeffer (Ms.)
MICRONIT MICROTECHNOLOGIES BV
Paesi Bassi
Contributo UE
€ 468 600
Indirizzo
Colosseum 15
7521 PV Enschede
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contatto amministrativo
Rene Koopman (Mr.)